Assess whether to resubmit, meet, or pause the program (c9bf71)

SITUATION A competitor label that just got a narrower indication put 505(b)(2) literature-to-product bridge table in front of pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / Clinical and Evidence Strategy close is to resubmit, meet, or from 505(b)(2) literature-to-product bridge table, and the live options are To resubmit, meet,, Pause the program.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; 505(b)(2) literature-to-product bridge table already has the discriminator after a competitor label that just got a narrower indication. 2. Keep Pause the program in force until 505(b)(2) literature-to-product bridge table is completed after a competitor label that just got a narrower indication for pediatric-plan strategist. 3. Treat 505(b)(2) literature-to-product bridge table as To resubmit, meet, because both readings appear after a competitor label that just got a narrower indication. 4. Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the decision to resubmit, meet, or turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a competitor label that just got a narrower indication and write the one fact that would move to resubmit, meet, or for pediatric-plan strategist.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication). If 505(b)(2) literature-to-product bridge table cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. Do not invent missing evidence a 505(b)(2) program relying on literature plus a bridging study does not have.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for pediatric-plan strategist - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Named option among To resubmit, meet,, Pause the program and the fact that kills the others - Owner and next date for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study